Cencora
COR
$308.37
-0.95%
Cencora, Inc. is a leading pharmaceutical wholesaler and healthcare solutions provider, distributing branded, generic, and specialty pharmaceuticals to pharmacies, hospitals, and healthcare providers across the U.S. and Europe. As one of the 'Big Three' domestic wholesalers alongside McKesson and Cardinal Health, Cencora commands over 90% combined market share in the U.S. pharmaceutical distribution industry, distinguishing itself through its scale, global specialty logistics (World Courier), and animal health distribution (MWI Animal Health). The current investor narrative centers on the company's strategic expansion into higher-margin commercialization services and international markets, while navigating a challenging operating environment marked by recent earnings volatility, a significant stock drawdown in May 2026, and ongoing debates about margin sustainability amid generic deflation and regulatory pressures.…
COR
Cencora
$308.37
Investment Opinion: Should I buy COR Today?
Based on the analysis, Cencora is rated a Hold. The stock offers a forward PE of 15.71x, which is reasonable, and the analyst consensus is Buy with an average target of $355.83, implying 14.3% upside. However, the high debt-to-equity ratio of 7.13x and thin margins (gross margin 3.16%) introduce significant risk. The stock is not a clear buy at current levels, but it is not a sell either, given the potential for earnings recovery.
Sign up to view all
COR 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock's forward valuation is reasonable, but the high leverage and thin margins create uncertainty. The recent earnings volatility (Q4 FY2025 loss) and the stock's underperformance suggest that the market is skeptical of the company's ability to deliver consistent growth. If the company can demonstrate margin stability and debt reduction, the stance would upgrade to bullish. Conversely, if margins deteriorate further or debt increases, the stance would become bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $356.67 and implied upside of +15.7% versus the current price.
Average Target
$356.67
0 analysts
Implied Upside
+15.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$320 - $412
Analyst target range
The target price range spans from a low of $310.00 to a high of $412.00, with the low essentially at the current price, suggesting that some analysts see limited downside, while the high implies a 32.3% upside. The wide spread of $102 between low and high targets reflects moderate uncertainty about the company's future performance, likely driven by the volatile earnings history and the ongoing integration of Alliance Healthcare. The high target assumes successful margin expansion and growth in commercialization services, while the low target prices in continued margin pressure and potential competitive losses. With no recent downgrades and several reaffirmations of positive ratings, the analyst community appears to view the recent stock weakness as an opportunity, though the lack of new upgrades suggests they are waiting for clearer signs of earnings stability.
Bulls vs Bears: COR Investment Factors
Cencora presents a classic value-versus-growth dilemma. The bull case rests on a compelling forward valuation (15.71x PE) and a 14-32% upside to analyst targets, supported by steady revenue growth and a defensive business model. The bear case highlights earnings volatility (trailing PE of 38.97x), a high PEG ratio (7.05x), and extreme leverage (debt-to-equity of 7.13x) that could amplify downside risks. Currently, the bearish evidence is slightly stronger given the recent earnings miss (Q4 FY2025 loss) and the stock's underperformance, but the forward multiple suggests the market is pricing in a recovery. The most critical tension is whether the company can convert its stable revenue base into consistent earnings growth, which would justify the forward PE and close the gap to the high target. If earnings stabilize and margins improve, the stock could re-rate upward; if not, the high leverage and thin margins could lead to further downside.
Bullish
- Forward PE at 15.7x with 32% upside: The forward PE of 15.71x is significantly lower than the trailing PE of 38.97x, indicating the market expects a strong earnings rebound. Analyst average target of $355.83 implies a 14.3% upside from the current price of $311.34, while the high target of $412.00 suggests a 32.3% potential gain.
- Revenue growth steady at 3.85%: Q2 FY2026 revenue grew 3.85% YoY to $78.36 billion, consistent with the prior quarter's 5.5% growth. This stability in a mature distribution industry demonstrates the company's ability to maintain market share and pricing power.
- Diversified segments add growth optionality: Animal Health contributed $1.44 billion and Other Segments $0.62 billion in Q2 FY2026, providing diversification beyond core pharma distribution. These higher-margin segments could drive margin expansion and reduce reliance on the low-margin wholesale business.
- Analyst consensus is Buy with no downgrades: With a recommendation mean of 1.57 (Buy) and 12 analysts covering, the consensus is positive. Recent actions include reaffirmations of positive ratings, indicating analysts view the May 2026 drawdown as an opportunity rather than a fundamental deterioration.
Bearish
- Trailing PE of 38.97x signals earnings volatility: The trailing PE is more than double the forward PE, reflecting depressed trailing earnings due to one-time charges and a loss in Q4 FY2025 (net income of -$339.7 million). This volatility makes historical valuation metrics unreliable and raises concerns about earnings quality.
- PEG ratio of 7.05x indicates overvaluation: Despite a forward PE of 15.71x, the PEG ratio of 7.05x suggests the stock is expensive relative to its expected growth rate. This implies the market is pricing in aggressive earnings growth that may not materialize, especially given the modest revenue growth of 3.85%.
- High debt-to-equity of 7.13x increases financial risk: Cencora's debt-to-equity ratio of 7.13x is extremely high, reflecting significant leverage from the Alliance Healthcare acquisition. This amplifies interest expense (Q2 FY2026: $154.3 million) and makes the company vulnerable to rising rates or margin compression.
- Gross margin only 3.16% with thin operating margin: Gross margin is a razor-thin 3.16%, and operating margin is just 1.14% (Q2 FY2026). This leaves little room for error; any cost inflation, generic deflation, or competitive pricing pressure could severely impact profitability.
COR Technical Analysis
Cencora's stock has been in a pronounced downtrend over the past year, with the price declining 8.1% year-to-date and 13.3% over the past six months, despite a modest 8.8% gain over the trailing twelve months. The current price of $311.34 sits at 82.5% of its 52-week range (between $244.82 low and $377.54 high), indicating the stock is trading well below its highs but has recovered significantly from its lows. This positioning suggests the market is still digesting the sharp correction from February's peak, with the stock having lost over 30% from its high before stabilizing in recent months.
Beta
0.57
0.57x market volatility
Max Drawdown
-32.6%
Largest decline past year
52-Week Range
$245-$378
Price range past year
Annual Return
+6.9%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | +4.0% | +1.7% |
| 3m | +0.8% | +4.7% |
| 6m | -6.5% | +10.4% |
| 1y | +6.9% | +21.9% |
| ytd | -9.0% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Cencora's revenue trajectory shows steady growth, with the most recent quarter (Q2 FY2026, ended March 31, 2026) reporting revenue of $78.36 billion, up 3.85% year-over-year. This growth rate is consistent with the prior quarter's 5.5% increase (Q1 FY2026 revenue of $85.93 billion), though it marks a deceleration from the 8.6% growth seen in Q3 FY2025. The company's revenue base is massive, but growth is modest, reflecting the mature nature of pharmaceutical distribution. Segment data reveals that Animal Health contributed $1.44 billion and Other Segments $0.62 billion in the latest quarter, indicating diversification beyond core distribution, though these segments remain a small portion of total revenue.
Quarterly Revenue
$78.4B
2026-03
Revenue YoY Growth
+3.9%
YoY Comparison
Gross Margin
4.2%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Given that Cencora is profitable (net income of $1.64 billion in the latest quarter), the appropriate valuation metric is the price-to-earnings (PE) ratio. The trailing PE stands at 38.97x, while the forward PE is 15.71x, implying the market expects significant earnings growth in the coming year. This wide gap suggests that the trailing earnings were depressed by one-time charges or cyclical factors, and the forward multiple is more reflective of normalized earnings power. The PEG ratio of 7.05x indicates that the stock is not cheap relative to its expected growth rate, which is a concern for value investors.
PE
39.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The debt-to-equity ratio of 7.13x is extremely high, reflecting the Alliance Healthcare acquisition, and interest expense of $154.3 million in Q2 FY2026 eats into profits. The company's net margin is only 0.48%, and gross margin is 3.16%, leaving minimal buffer for cost increases or pricing pressure. Earnings have been volatile, with a net loss of $339.7 million in Q4 FY2025, and the trailing PE of 38.97x indicates that historical earnings are depressed. Free cash flow of $1.56 billion (TTM) is positive but modest relative to the $60.6 billion market cap, limiting financial flexibility.